BioMarin Pharmaceutical (BMRN) News Today → Elon Musk’s PRIME is Set to Shock the World (From InvestorPlace) (Ad) Free BMRN Stock Alerts $77.56 +0.59 (+0.77%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 18 at 10:58 AM | wsj.comBioMarin Pharmaceutical Inc.May 18 at 6:37 AM | marketbeat.comBaird R W Downgrades BioMarin Pharmaceutical (NASDAQ:BMRN) to HoldBaird R W cut shares of BioMarin Pharmaceutical from a "strong-buy" rating to a "hold" rating in a research note on Friday.May 18 at 5:32 AM | americanbankingnews.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Short Interest Up 6.0% in AprilMay 18 at 4:52 AM | americanbankingnews.comShort Interest in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Expands By 6.0%May 17 at 11:22 PM | msn.comBaird Downgrades BioMarin Pharmaceutical (BMRN)May 17 at 1:21 PM | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: BioMarin Pharmaceutical (BMRN), Ionis Pharmaceuticals (IONS)May 17 at 8:00 AM | marketbeat.comRobert W. Baird Downgrades BioMarin Pharmaceutical (NASDAQ:BMRN) to NeutralRobert W. Baird downgraded shares of BioMarin Pharmaceutical from an "outperform" rating to a "neutral" rating and reduced their price target for the company from $104.00 to $72.00 in a report on Friday.May 17 at 2:34 AM | americanbankingnews.comQ2 2024 EPS Estimates for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Reduced by Zacks ResearchMay 16 at 7:51 AM | marketbeat.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to Post Q2 2024 Earnings of $0.36 Per Share, Zacks Research ForecastsBioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) - Equities researchers at Zacks Research cut their Q2 2024 EPS estimates for shares of BioMarin Pharmaceutical in a report released on Monday, May 13th. Zacks Research analyst S. Ganoria now forecasts that the biotechnology company will posMay 16 at 2:30 AM | americanbankingnews.comZacks Research Comments on BioMarin Pharmaceutical Inc.'s Q3 2024 Earnings (NASDAQ:BMRN)May 15 at 9:55 AM | seekingalpha.comBioMarin: Short-Term Headwinds But Long-Term Opportunities RemainMay 15 at 7:49 AM | marketbeat.comZacks Research Analysts Raise Earnings Estimates for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) - Equities researchers at Zacks Research upped their Q3 2024 earnings per share estimates for shares of BioMarin Pharmaceutical in a research note issued on Monday, May 13th. Zacks Research analyst S. Ganoria now expects that the biotechnolMay 15 at 6:22 AM | americanbankingnews.comBioMarin Pharmaceutical (NASDAQ:BMRN) Coverage Initiated at Evercore ISIMay 14, 2024 | bizjournals.comBioMarin cutting about 170 jobs after shuffling drug portfolioMay 14, 2024 | marketbeat.comThornburg Investment Management Inc. Sells 105,276 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Thornburg Investment Management Inc. reduced its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 38.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 170,802 shares of the bioMay 14, 2024 | marketwatch.comBioMarin Pharmaceutical to Discontinue Certain R&D Programs, Cut About 170 JobsMay 14, 2024 | msn.comEvercore ISI Group Initiates Coverage of BioMarin Pharmaceutical (BMRN) with Outperform RecommendationMay 14, 2024 | americanbankingnews.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Director Jean Jacques Bienaime Sells 20,000 Shares of StockMay 14, 2024 | insidertrades.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Director Jean Jacques Bienaime Sells 20,000 SharesMay 13, 2024 | marketbeat.comJean Jacques Bienaime Sells 20,000 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) StockBioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Get Free Report) Director Jean Jacques Bienaime sold 20,000 shares of the company's stock in a transaction dated Thursday, May 9th. The stock was sold at an average price of $81.62, for a total transaction of $1,632,400.00. Following the completion of the sale, the director now owns 474,994 shares in the company, valued at approximately $38,769,010.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.May 11, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Acquires 74,100 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Charles Schwab Investment Management Inc. boosted its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 5.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,378,897 shMay 10, 2024 | marketbeat.comFisher Asset Management LLC Purchases New Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Fisher Asset Management LLC acquired a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 13,266 shares of the biotechnology company's stock, valued at approximatelyMay 9, 2024 | investorplace.comThe 3 Best Biotech Stocks to Buy in May 2024May 9, 2024 | americanbankingnews.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Receives Consensus Rating of "Moderate Buy" from BrokeragesMay 8, 2024 | prnewswire.comBioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NVMay 7, 2024 | marketbeat.comNational Bank of Canada FI Sells 342,304 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)National Bank of Canada FI reduced its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 56.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 268,607 shares of the biotechnology compMay 7, 2024 | insidertrades.comInsider Selling: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) EVP Sells 1,850 Shares of StockMay 6, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: RxSight (RXST) and BioMarin Pharmaceutical (BMRN)May 6, 2024 | markets.businessinsider.comBioMarin Pharmaceutical Hold Rating: Potential for Voxzogo Label Expansion Amidst Early Data and Upcoming TrialsMay 6, 2024 | finance.yahoo.comInsider Sale: EVP, Chief Commercial Officer Jeffrey Ajer Sells 5,000 Shares of Biomarin ...May 6, 2024 | marketbeat.comGeorge Eric Davis Sells 1,850 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) StockBioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Get Free Report) EVP George Eric Davis sold 1,850 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $85.01, for a total value of $157,268.50. Following the transaction, the executive vice president now owns 56,157 shares of the company's stock, valued at $4,773,906.57. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.May 6, 2024 | marketbeat.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Sold by Swiss National BankSwiss National Bank reduced its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 2.6% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 588,400 shares of the biotechnology company's stock after selling 15,400 shares during the period. SwissMay 4, 2024 | prnewswire.comNew Data for BioMarin's VOXZOGO® (vosoritide) for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual MeetingMay 3, 2024 | investorplace.comCiti Just Cut Its Price Target on These 3 StocksMay 2, 2024 | marketbeat.comVan ECK Associates Corp Has $12.93 Million Stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Van ECK Associates Corp trimmed its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 13.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 134,096 shares ofApril 30, 2024 | msn.comBiotech Sector: M&A Fuels Renewed ExcitementApril 30, 2024 | finance.yahoo.comBioMarin Pharmaceutical Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This YearApril 30, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), BioMarin Pharmaceutical (BMRN) and Hookipa Pharma (HOOK)April 29, 2024 | finance.yahoo.comBioMarin Pharmaceutical Investors Overfocused on Roctavian, Distracted From Enzyme Replacement Therapies, UBS SaysApril 28, 2024 | marketbeat.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Short Interest Up 20.6% in AprilBioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Get Free Report) saw a large increase in short interest in April. As of April 15th, there was short interest totalling 3,690,000 shares, an increase of 20.6% from the March 31st total of 3,060,000 shares. Based on an average daily trading volume, of 1,410,000 shares, the days-to-cover ratio is currently 2.6 days.April 28, 2024 | marketbeat.comMotley Fool Wealth Management LLC Sells 18,667 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Motley Fool Wealth Management LLC reduced its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 3.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 470,289 shares of the biApril 27, 2024 | marketbeat.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Acquired by C WorldWide Group Holding A SC WorldWide Group Holding A S increased its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 19.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 303,851 shares of the biotechApril 27, 2024 | finance.yahoo.comBeyond the Balance Sheet: What SWOT Reveals About Biomarin Pharmaceutical Inc (BMRN)April 26, 2024 | marketbeat.comBioMarin Pharmaceutical (NASDAQ:BMRN) PT Lowered to $112.00Morgan Stanley dropped their price target on shares of BioMarin Pharmaceutical from $115.00 to $112.00 and set an "overweight" rating on the stock in a research report on Friday.April 26, 2024 | msn.comToday's Stocks Selling Off: Intel, Biomarin, TextronApril 26, 2024 | markets.businessinsider.comBuy Rating Affirmed for BioMarin Pharmaceutical Amidst Strong Earnings and Voxzogo’s Growth PotentialApril 26, 2024 | finance.yahoo.comBioMarin Pharmaceutical First Quarter 2024 Earnings: EPS Beats ExpectationsApril 25, 2024 | finanznachrichten.deBioMarin Pharmaceutical Inc.: BioMarin Reports Record Financial Results for the First Quarter 2024April 25, 2024 | markets.businessinsider.comScotiabank Reaffirms Their Hold Rating on BioMarin Pharmaceutical (BMRN)April 25, 2024 | marketbeat.comBioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Cut to $91.00Citigroup cut their price target on BioMarin Pharmaceutical from $94.00 to $91.00 and set a "neutral" rating for the company in a report on Thursday. Get BioMarin Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter. Email Address get a piece of the profit from this land (Ad)This isn’t the prettiest land on earth. But it might be the most valuable. And you don’t have to own, lease, or rent any land. Click here to see my #1 investment for 2024. BMRN Media Mentions By Week BMRN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BMRN News Sentiment▼0.270.50▲Average Medical News Sentiment BMRN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BMRN Articles This Week▼317▲BMRN Articles Average Week Get BioMarin Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ALNY News Today UTHR News Today IONS News Today MDGL News Today MRTX News Today ALKS News Today TEVA News Today BGNE News Today VTRS News Today SRPT News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BMRN) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceI’m afraid WWIII is a very real possibility Porter & CompanyPOTUS in ‘25 Not Biden/Trump, ButThe Freeport SocietyMissed NVDA? Buy this AI stock NOWChaikin AnalyticsUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioMarin Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
